GSK-1292263

DB12627InvestigationalSmall molecule

GSK1292263 has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.

Mechanism: Pharmacologically active on Glucose-dependent insulinotropic receptor
Curator reviewed
Formula / weight: C₂₃H₂₈N₄O₄S · 456.56 g/mol (avg)
Code names: GSK-1292263

Resolves to

Compound

Structure

InChIKeyAYJRTVVIBJSSKN-UHFFFAOYSA-NSMILESCC(C)C1=NOC(=N1)N1CCC(COC2=CC=C(N=C2)C2=CC=C(C=C2)S(C)(=O)=O)CC1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with GSK-1292263, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.